Drug
Drug Bgm0504 Administered
Drug Bgm0504 Administered: highest development phase Phase 3, developed by BrightGene Bio-Medical Technology Co., Ltd.. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- BrightGene Bio-Medical Technology Co., Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| Drug: : 10 mg BGM0504 Administered SC NCT06716203 | Phase 3 | Type 2 Diabetes Mellitus (T2DM) |
| Drug: 5 mg BGM0504 Administered SC NCT06716216 | Phase 3 | Type 2 Diabetes Mellitus (T2DM) |
Latest
No recent events.
Follow Drug Bgm0504 Administered on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.